热门资讯> 正文
Acrivon Therapeutics报告第四季度业绩
2025-03-28 17:20
- Acrivon Therapeutics press release (NASDAQ:ACRV): Q4 GAAP EPS of -$0.60.
- As of December 31, 2024, the company had cash, cash equivalents and investments of $184.6 million, which is expected to fund operating expenses and capital expenditure requirements into 2027.
More on Acrivon Therapeutics
- Acrivon Therapeutics gets FDA breakthrough device designation for its oncosignature assay for endometrial cancer
- Seeking Alpha’s Quant Rating on Acrivon Therapeutics
- Historical earnings data for Acrivon Therapeutics
- Financial information for Acrivon Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
